The Excessive Daytime Sleepiness Market in the United States is poised for significant growth between 2025 and 2035, driven by rising prevalence of sleep disorders, lifestyle-induced sleep challenges, and increasing public awareness around sleep health. Valued at approximately USD 6,248 million in 2025, the market is expected to nearly double to USD 14,982 million by 2035, registering a robust CAGR of 9.1% over the forecast period.
Explore trends before investing – request a sample report today! → https://www.futuremarketinsights.com/reports/sample/rep-gb-12553
Market Dynamics Driving Growth
The growth trajectory of the U.S. EDS market is propelled by an increasing diagnosis of sleep disorders such as narcolepsy, sleep apnea, and restless leg syndrome, all of which manifest as daytime fatigue. The rising incidence of obstructive sleep apnea (OSA) among elderly and obese populations has placed additional demand on both pharmacological and device-based interventions.
Despite progress, underdiagnosis remains a critical challenge, delaying early intervention and prompting medical practitioners to invest in awareness campaigns, advanced diagnostic equipment, and early-stage treatment programs. This gap presents an opportunity for innovation in patient engagement and home-based monitoring technologies.
Treatment Landscape
The market comprises three primary treatment modalities: medical devices, pharmacological therapies, and cognitive-behavioral interventions. Drug therapies such as modafinil and solriamfetol are standard treatments for EDS caused by narcolepsy and sleep apnea. CPAP devices remain the gold standard for OSA-related daytime sleepiness, while cognitive-behavioral therapy (CBT) is emerging as an effective non-pharmacologic solution to improve sleep hygiene and reduce daytime fatigue.
Regional Insights
North America leads the global EDS market due to high prevalence of sleep disorders, strong healthcare infrastructure, and early adoption of innovative treatment options. U.S. sleep clinics are expanding, and awareness campaigns by professional organizations are driving early diagnosis and intervention. Telemedicine, AI-enabled diagnostic tools, and wearable sleep trackers are gaining traction, allowing patients to monitor sleep patterns and seek timely medical guidance.
Europe maintains a strong market position, with France, Germany, and the United Kingdom driving growth. Regulatory oversight by the European Medicines Agency ensures drug safety, while reimbursement policies improve access to medical devices. Increasing recognition of behavioral therapies reflects growing awareness of mental health’s role in sleep quality.
Asia-Pacific represents a high-growth market due to rising urbanization, lifestyle changes, and undiagnosed sleep disorders. Japan’s aging population, China’s expanding diagnostic capabilities, and South Korea’s adoption of smart sleep technologies are key market drivers. However, affordability and accessibility remain challenges in the region, prompting governments and private firms to expand sleep health programs and diagnostic centers.
Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates – https://www.futuremarketinsights.com/reports/brochure/rep-gb-12553
Challenges and Opportunities
The primary challenge in the EDS market is underdiagnosis due to limited access and awareness. Patients often misattribute symptoms to stress or fatigue, delaying effective treatment. Education campaigns, wider screening programs, and home-based monitoring solutions are addressing these gaps.
Digital health solutions represent a major opportunity. AI-powered diagnostic software, telemedicine consultations, and smart CPAP devices are revolutionizing care by improving accessibility and treatment adherence. Additionally, pharmaceutical innovation in wake-promoting agents with fewer side effects is expanding treatment options.
Market Shifts and Future Trends
From 2020 to 2024, CPAP devices saw significant growth due to rising OSA diagnoses and insurance coverage expansion. Moving forward, 2025–2035 will see a shift toward personalized, technology-enabled solutions, including AI-driven sleep diagnostics, wearable monitors, and digital therapeutics. Non-pharmacological treatments such as CBT-I are expected to gain prominence, supported by mobile therapeutic platforms and corporate wellness programs focusing on improved sleep habits.
Competitive Landscape
The U.S. EDS market is dynamic, with no single dominant player. Key competitors include:
- Jazz Pharmaceuticals (25–30%) – Sodium oxybate products Xyrem and Xywav for narcolepsy and idiopathic hypersomnia.
- Teva Pharmaceutical (15–20%) – Provigil (modafinil) for EDS management across narcolepsy, OSA, and shift work disorder.
- Avadel Pharmaceuticals (10–15%) – Lumryz, a once-nightly sodium oxybate therapy.
- Axsome Therapeutics (5–10%) – Sunosi (solriamfetol) dual-mechanism wakefulness therapy.
- Bioprojet Pharma (3–7%) – Wakix (pitolisant), a histamine-3 receptor antagonist for EDS in narcolepsy.
Other notable players contributing 25–35% of the market include Harmony Biosciences, Takeda Pharmaceutical Company, and Eisai Co., Ltd.
Distribution Channels
Hospitals and sleep laboratories remain the primary distribution channels due to comprehensive diagnostic and therapeutic services. Home care settings are expanding with telemedicine and portable sleep monitoring devices, particularly for CPAP users, reflecting a trend toward patient-centered care and convenience.
Why Choose FMI Empowering Decisions that Drive Real-World Outcomes: https://www.futuremarketinsights.com/why-fmi
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
